Andre Goy, MD, John Theurer Cancer Center

Articles by Andre Goy, MD, John Theurer Cancer Center

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

ByAndre Goy, MD, John Theurer Cancer Center

March 29th 2024

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

Dr Goy on the Influence of High-Risk Features on Treatment Decision-Making in MCL

ByAndre Goy, MD, John Theurer Cancer Center

December 5th 2023

Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.

Dr. Goy on the Management of Patients With Genetic Abnormalities and Low Risk in MCL

ByAndre Goy, MD, John Theurer Cancer Center

March 14th 2023

Andre H. Goy, MD, discusses the appropriate monitoring and management of patients with mantle cell lymphoma who display genetic abnormalities but are not considered to be high risk.

Andre H. Goy, MD, physician in chief, Hackensack Meridian Health Oncology Care Transformation Service, chairman & chief physician officer, John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology, Hackensack Meridian School of Medicine at Seton Hall University, professor of medicine, Georgetown University

Dr. Goy on Different Presentations of MCL

ByAndre Goy, MD, John Theurer Cancer Center

March 13th 2023

Andre H. Goy, MD, discusses differentiating between disease presentations in mantle cell lymphoma.

Dr. Goy on Updates in Precision Medicine in Hematologic Malignancies

ByAndre Goy, MD, John Theurer Cancer Center

September 15th 2022

Andre H. Goy, MD, discusses updates in precision medicine.

Dr. Goy on the Importance of Refined Decision Making With Precision Medicine

ByAndre Goy, MD, John Theurer Cancer Center

September 20th 2021

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

Andre H. Goy, MD, of John Theurer Cancer Center

Dr. Goy on the Durability of Response With Brexucabtagene Autoleucel in MCL

ByAndre Goy, MD, John Theurer Cancer Center

May 6th 2021

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Goy on the Potential Utility of Liso-Cel in MCL

ByAndre Goy, MD, John Theurer Cancer Center

April 19th 2021

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

ByAndre H. Goy, MD,Andre Goy, MD, John Theurer Cancer Center

April 8th 2021

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

ByAndre Goy, MD, John Theurer Cancer Center

March 12th 2021

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Dr. Goy on Updates in Precision Medicine in Oncology

ByAndre Goy, MD, John Theurer Cancer Center

September 26th 2020

Andre Goy, MD, MS, discusses updates in precision medicine.

Novel Therapies: R2-GDP-GOTEL and Smart Start

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Regimen FDA Approval

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Overview

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Clinical Trials

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Response Rates

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

ByAndre Goy, MD, John Theurer Cancer Center

June 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Goy on Promising Data With Acalabrutinib in MCL

ByAndre Goy, MD, John Theurer Cancer Center

February 19th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses promising data with acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Goy on Immunotherapy in Mantle Cell Lymphoma

ByAndre Goy, MD, John Theurer Cancer Center

September 5th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Dr. Goy on the Combination of Biological Therapies in Relapsed MCL

ByAndre Goy, MD, John Theurer Cancer Center

August 3rd 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

ByAndre Goy, MD, John Theurer Cancer Center

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).